- Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi®) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF)
- Initial results of a Phase 1/2 study evaluating the safety and tolerability of INCB00928, an ALK2 inhibitor, show INCB00928 improves anemia in patients with MF both as monotherapy and in combination with ruxolitinib
- These studies are part of our LIMBER program evaluating ruxolitinib combinations and potential new targets for appropriate patients with myeloproliferative neoplasms (MPNs)
/PRNewswire/ Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help.
/PRNewswire/ Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help.
CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing.